DYN
Dyne Therapeutics, Inc.
Biotechnology · Healthcare · United States
16.69
close · 2026-10-30
value
66
cheaper than peers66
quality
36
stronger fundamentals36
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -5.0% | 69 |
| cash flow yield, 2 years ago | -6.1% | 66 |
| earnings yield, 3 years ago | -19.4% | 65 |
| cash flow yield, 1 year ago | -9.5% | 62 |
| earnings yield, 2 years ago | -23.7% | 60 |
| cash flow yield, latest year | -13.6% | 57 |
| earnings yield, 1 year ago | -20.2% | 56 |
| earnings yield, latest year | -20.8% | 55 |
| price to book | 3.94× | 33 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -58.9% | 54 |
| operating margin | 0.0% | 50 |
| debt to equity | 19.5% | 27 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$292.3M |
| employees | 263 |
| first trade | 2020-09-17 |
| next earnings | not reported |
| fundamentals updated | 2026-07-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.47 | -3.37 | -3.95 | -3.23 |
| free cash flow | -$423.9M | -$294.7M | -$188.9M | -$156.7M |
| net income | -$446.2M | -$317.4M | -$235.9M | -$168.1M |
| revenue | $0 | $0 | $0 | $0 |